ABSTRACT

Background
A subset of fludarabine-resistant chronic lymphocytic leukemia patients has previously been shown to express elevated intracellular levels of the concentrative high-affinity fludarabine transporter hCNT3, without any detectable related activity. We have recently shown that all-trans-retinoic acid is capable of inducing hCNT3 trafficking to plasma membrane in the MEC1 cell line. We therefore evaluated the effect of all-transretinoic acid on hCNT3 in primary chronic lymphocytic leukemia cells as a suitable mechanism to improve fludarabine-based chronic lymphocytic leukemia therapy.
Design and Methods
Twenty-three chronic lymphocytic leukemia patients wild-type for P53 were analyzed for the ex vivo sensitivity to fludarabine. hCNT3 activity in chronic lymphocytic leukemia cell samples was evaluated by measuring the uptake of [8- 3 H]-fludarabine. The amount of TGFβ1 and hCNT3 mRNA was analyzed by real-time PCR. The effect of all-transretinoic acid on hCNT3 subcellular localization was analyzed by confocal microscopy and its effect on fludarabine induced apoptosis was evaluated by flow cytometry analysis using Annexin V staining.
Results
Chronic lymphocytic leukemia cases showing higher ex vivo basal sensitivity to fludarabine also had a greater basal hCNT3-associated fludarabine uptake capacity compared to the subset of patients showing ex vivo resistance to the drug. hCNT3
transporter activity in chronic lymphocytic leukemia cells from the latter patients was either negligible or absent. Treatment of fludarabine-resistant chronic lymphocytic leukemia subset cells with all-trans-retinoic acid induced increased fludarabine transport via hCNT3 that was associated with a significant rise in fludarabine sensitivity.
Conclusions
Improvement of ex vivo fludarabine sensitivity in chronic lymphocytic leukemia cells is associated with increased hCNT3 activity after all-trans-retinoic acid treatment.
INTRODUCTION
Chronic lymphocytic leukemia (CLL) is a common type of adult leukemia characterized by the persistent accumulation of CD5+ B lymphocytes (1) , primarily due to defects in apoptosis. The disease has a highly variable clinical course and treatment is usually restricted to patients with advanced and symptomatic disease. Fludarabine, a purine nucleoside analog, has long been a major choice for CLL chemotherapy. This drug is cytotoxic both against dividing and resting cells (2) (3) . In dividing cells, fludarabine inhibits ribonucleotide reductase and DNA synthesis (4) (5) , whereas in quiescent cells the main mechanism of cytotoxicity appears to be inhibition of cellular DNA repair processes leading to induction of apoptosis (6) (7) . Fludarabine monotherapy is associated with higher rates, long lasting complete remission and improved overall response when compared with treatment with alkylating agents (8) (9) (10) (11) . However, since the late 1990s, combinatory chemotherapies have become the recognized gold standards of care. Purine analogs and alkylating agents differ in terms of mechanisms of action, and thus exhibit partially nonoverlapping toxicity profiles. Moreover, synergistic effects are evident when therapy with two such compounds is prescribed (12) (13) (14) (15) . More recent reports suggest that the administration of monoclonal antibodies as rituximab can significantly improve the course of CLL. In this sense the latest results
show that chemoimmunotherapy such as FCR (fludarabine, cyclophosphamide, and rituximab) is the optimal first-line treatment, however, some patients do not respond to this regimen (16) (17) (18) . Resistance to fludarabine is a major problem in CLL treatment. As a DNA-damaging agent, fludarabine increases P53 levels by promoting posttranslational stabilization of the protein, thereby inducing P53-dependent cell death.
Although mutations in the P53 gene have been correlated with resistance to fludarabine and reduced patient survival (19) (20) (21) , the nucleoside analog can also induce apoptosis of CLL cells in vitro in a P53-independent manner (22) . Furthermore, the cellular microenvironment likely influences chemoresistance. Marrow stromal cells protect CLL cells from fludarabine, dexamethasone, and cyclophosphamide by a mechanism requiring cell-cell contact (23) . Indeed, several mechanisms may contribute to fludarabine resistance in patients wild-type for P53.
Before entering cells, fludarabine is rapidly dephosphorylated by membrane ectonucleotidases (CD73) and then transported inside the cell via nucleoside-selective DOI: 10.3324/haematol.2011.051557 plasma membrane transporters. Once inside the cell, the drug is phosphorylated by deoxycytidine kinase (DCK) before cytotoxic activity can be exerted (5, 24) . Nucleoside uptake into cells is mediated by specific nucleoside transporter (NT) proteins belonging to two unrelated gene families, SLC28 and SLC29, encoding CNT (concentrative nucleoside transporter) and ENT (equilibrative nucleoside transporter) proteins, respectively (25) (26) . Previous work by our group showed that primary CLL cells coexpress hENT1, hENT2, hCNT2, and hCNT3, but accumulation of fludarabine in CLL cells is mediated mostly, if not exclusively, by ENT-type transporters (27) . hCNT3 but not hCNT2 can also transport fludarabine (28) (29) (30) . Indeed, hCNT3 is even more efficient than is hENT2 in this regard; the former transporter has a higher affinity for the drug and, more importantly, it is a CNT, thus concentrating nucleoside analogs inside cells. Moreover, we sought to determine whether the effect of ATRA on hCNT3, described to date only in a cell line (33) , was evident in primary CLL cells. This would provide a basis for modulating fludarabine-based therapies.
DESIGN AND METHODS
Chemicals and Reagents
ATRA and TGFβ1 were purchased from Sigma-Aldrich. expression level was quantified as previously described (35) . 
Fludarabine transport assay
For transport measurements, CLL cells were assessed immediately after thawing or after incubation at 37ºC for different periods with or without ATRA. Uptake of H]-fludarabine (1 µ M) was measured using a rapid filtration method adapted from a technique previously described (38) . Cells were resuspended in either NaCl-or choline chloride buffer. Both ENT-and CNT-type proteins are functional in the presence of sodium, although only CNTs are sodium-dependent. This means that, in the absence of the cation, only ENTs will be active. Accordingly, sodium-dependent nucleoside uptake (CNT-associated) was calculated by subtracting the uptake rate measured in choline chloride-containing buffer (almost exclusively associated with ENT1 and ENT2 activities) from that obtained using sodium-containing buffer (in which both ENTs and CNTs are active).
RNA isolation and quantitative RT-PCR
Total RNA was isolated using the TRIzol reagent (Invitrogen). One microgram of total DNase-treated RNA was used to generate cDNA, using M-MLV Reverse
Transcriptase and random hexamers for reverse transcription (Life Technologies). RNA retrotranscription and RT-PCR were performed as previously described (33) . 
Statistical analysis
The statistical significance between groups was analyzed using Student's t -test.
In Figure legends , ***p≤0.001, **p≤0.01, and *p≤0.05 indicate significant difference between treatments.
RESULTS
Sensitivity of primary chronic lymphocytic leukemia cells to fludarabine
Fludarabine sensitivity was evaluated ex vivo in cells from 23 CLL patients who were wild-type for TP53, consisting of 10 women and 13 men with a median age at the time of CLL diagnosis of 62.3 years (range, 44-88 years). General clinical and biological features of these patients are shown in Table 1 .
CLL cells were cultured with fludarabine (10 µg/mL) for 90 min, washed twice in PBS, and next cultured in drug-free complete medium for additional 48 h, at which time cytotoxicity was assessed by annexin V/PI staining. A heterogeneous profile of sensitivities to the nucleoside analog was observed among patients, with relative apoptotic rates ranging from 0 to 44% above basal levels. This allowed us to split the cohort into two subsets, either resistant or sensitive to fludarabine, as determined by choice of an arbitrary threshold (a 10% increase in fludarabine-induced apoptosis compared to that of control non-treated CLL cells [ Table 1 hENT-mediated sodium-independent transporters (data not shown) whereas sodiumcoupled fludarabine transport was very low or even negligible in the cells of some CLL cases ( Figure 2A) . Interestingly, ATRA treatment of CLL cells caused a timedependent increase in sodium-coupled fludarabine uptake (Fig. 2A) ; the peak of activity occurred 5-6 h after ATRA treatment. As mentioned above, CLL cells express only the hCNT2 and hCNT3 concentrative transporters, and, of these, only hCNT3 transports fludarabine, thus suggesting that hCNT3 activity is upregulated in ATRA-treated cells from fludarabine-resistant CLL patients.
We also analyzed the effect of ATRA on primary cells from three CLL patients that were shown to be sensitive to fludarabine ex vivo. In contrast to the results described above, drug-sensitive CLL cells showed significant basal hCNT3 activity that was minimally affected by ATRA treatment (Fig. 2B) . In addition to the three samples in (Fig. 4A) , whereas fludarabine-resistant cells (12 cases) showed significantly elevated apoptotic levels after pre-treatment with ATRA when fludarabine was used at 10 µ g/mL, a dose to which the cells were completely insensitive when the drug was employed alone for 90 min ( Figure 4B ).
We previously showed that TGFβ1 is involved in the effect triggered by ATRA in the chronic lymphocytic leukemia cell line MEC1 (33) . In the present study, we demonstrated that ATRA induced TGFβ1 expression in primary CLL cells. To evaluate the role played by TGFβ1 in fludarabine-triggered cytotoxicity, CLL cells were cultured in the presence of TGFβ1 for 40 min before addition of fludarabine (10 µ g/mL for 90 min). Apoptosis levels were measured 48 h later by annexin V/PI staining. As shown in Figure 5A , a significant increase in fludarabine induced-apoptosis was evident in cells from drug-resistant patients (n=12) when the cells were pretreated with TGFβ1. On the other hand, TGFβ1 had no effect on apoptosis triggered by fludarabine in drug-sensitive cells (n=11) ( Figure 5B ).
The effect of all-trans-retinoic acid on the cytotoxicity of non-nucleosidederived drugs in chronic lymphocytic leukemia cells
The possibility that ATRA could sensitize CLL cells to apoptosis triggered by any cytotoxic anticancer drug, which would indicate that induction of fludarabine-triggered cytotoxicity was nonspecific, was addressed by testing the effects triggered by two antineoplastic agents, the proteasome inhibitor bortezomib (5 nM) and the glucocorticoid steroid dexamethasone (1.5 µM), neither of which is taken up via a nucleoside transporter. CLL cells were pretreated with ATRA for 5 h before addition of either bortezomib or dexamethasone for 90 min. Cells were next washed and cultured for further 48 h in drug-free complete medium. Neither ATRA nor TGFβ1 increased the extent of apoptosis induced by either cytotoxic drug in any cell sample tested ( Figure 6 ).
DISCUSSION
The nucleoside analog fludarabine is one of the most effective drugs in the treatment of CLL. However, some patients do not adequately respond to such therapy and that is why the treatment of fludarabine refractory disease is so important nowadays (40) (41) . Previous studies disclosed a correlation between intracellular expression of the broad-selectivity nucleoside drug transporter hCNT3 and reduced patient time-to-progression (42) . Also, on the basis of a study from our laboratory in a CLL-derived cell line that showed regulated trafficking of hCNT3 into the plasma membrane (33), we hypothesized that early steps (i.e., transport across the plasma membrane) in the pharmacological action of fludarabine may be a limiting factor for induction of cytotoxicity in fludarabine-resistant patients wild-type for P53, thereby becoming suitable targets for therapy improvement. The present study provides "proof of concept" evidence demonstrating that modulation of transport function in primary CLL cells improves chemosensitivity in this subset of CLL patients. A model of hCNT3-regulated trafficking in MEC-1 cells recently developed by our group suggests that ATRA can promote movement of hCNT3-enriched vesicles into the plasma membrane (33) . Furthermore, we have previously shown that primary CLL cells only express hCNT2 and hCNT3 as sodium-coupled nucleoside transporters (27) . Thus, since hCNT2 is not a fludarabine transporter, fludarabine uptake can only be mediated by hCNT3 (27) . In fact, here it was shown that ex vivo treatment of fludarabine-resistant primary CLL cells with ATRA resulted in an increase in fludarabine influx and enhanced cytotoxicity.
ATRA seems to have a variety of effects on CLL cells, apart from the novel posttranslational regulation of a drug transporter described in the present study. ATRA induces apoptosis, in a dose-dependent manner, in CLL cells treated with the drug for 48 h (43) , and this effect is mediated by caspase-3 activation. In our experiments, ATRA alone did not significantly induce apoptosis in cell samples tested, probably because ATRA treatment was only 5 to 6 h in duration in our model. In any case, any ATRA-triggered pro-apoptotic effect on CLL cells would benefit patients further.
As ATRA increases TGFβ1 mRNA levels, and considering that the cytokine itself potentiates fludarabine action, it is very likely that the enhanced fludarabine sensitivity of primary CLL cells is mediated by a similar mechanism, if not identical, to that recently described in the MEC-1 CLL cell line. Moreover, neither ATRA nor TGF-β1 induced any change either in the amounts of hCNT3 mRNA or protein (not shown). Thus, the increase in hCNT3-related function after ATRA addition cannot be the result of changes in hCNT3 expression levels, in accordance with the observations in MEC1 cells (33) .
This might be consistent with the fact that ATRA promotes expression and release of TGFβ1, which then would enhance the trafficking of hCNT3-enriched vesicles into the plasma membrane (33) .
In summary, the data of the present work support the view that the fludarabine resistance of primary CLL cells from patients wild-type for P53 can be overcome, to a significant extent, by ATRA treatment, leading to TGFβ1 synthesis and, probably, to a change in the subcelullar localization of hCNT3. In fact, fludarabine-resistant untreated cells were shown to contain high intracellular levels of hCNT3 protein, in line with previous observations (31) .
On the other hand, CLL cells from the subset of patients showing ex vivo sensitivity to fludarabine had significant basal hCNT3-related activity, indicating that such cells could take up the drug more efficiently under basal conditions. Such uptake, even if moderately low, might be adequate to sustain the hCNT3 concentrative capacity required to potentiate the pharmacological action of fludarabine. It may be argued that hENT-related activity of both drug-resistant and -sensitive cell populations could mediate fludarabine-related effects, but hENTs show lower affinity for fludarabine than hCNT3 and, more importantly, hENTs mediate bidirectional transport across the plasma membrane, whereas hCNT3 is a highly concentrative drug influx transporter, as two sodium ions are translocated along with every drug molecule (29, 44) . This makes hCNT3 a suitable target for chemotherapeutic intervention in tumor cells in which hCNT3 intracellular stores may be present and eventually recruited to the plasma membrane, thereby enhancing the drug uptake capacity of such cells.
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